Clinical Trials Logo

High Risk HLA-A2+ Melanoma clinical trials

View clinical trials related to High Risk HLA-A2+ Melanoma.

Filter by:
  • None
  • Page 1

NCT ID: NCT01861938 Not yet recruiting - Metastatic Disease Clinical Trials

Modified Melanoma Vaccine for High Risk or Low Residual Disease Patients

Start date: June 2013
Phase: Phase 2/Phase 3
Study type: Interventional

This study is based on the hypothesis that stimulation of the immune response against the tumor can help destroy residual tumor in melanoma patients with very high risk for disease recurrence and in patients with relatively low tumor burden who already got first line treatment for their disease. Ongoing clinical trials in the Hadassah Hospital have shown that vaccination of patients with a cell line of tumor cells from the patient himself, or with a combination of three cell lines that partially match the patient's cell characteristics, could improve the immune response against the tumor, was associated with improved disease-free and overall survival. In this study, the investigators will evaluate the efficacy of a modified tumor cell vaccine, in terms of immune response,improved disease-free and overall survival. The vaccine consists of a cell line that has a high expression level of melanoma molecules, and has been genetically modified to induce a strong immune response.